Payment overview · 2025
General Payments
$1,170.84
60 reported records · 14 companies
Healthcare provider profile · identity verified
Melissa Mercado, DO
Allopathic & Osteopathic Physicians|Family Medicine · JERSEY CITY, NJ · NPI 1821587270
Verified facts
What the public records show
CMS Open Payments records show Melissa Mercado, DO received $1,170.84 in general payments during 2025 across 60 reported records.
Salix Pharmaceuticals, a division of Bausch Health US, LLC accounted for 15.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Entresto, Jardiance, Kerendia, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 161 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Synjardy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 123 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 161 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $185.25 | 15.8% | 10 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $142.74 | 12.2% | 7 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $135.10 | 11.5% | 7 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $114.46 | 9.8% | 7 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $112.55 | 9.6% | 7 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $107.65 | 9.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $101.83 | 8.7% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $97.02 | 8.3% | 6 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $81.97 | 7.0% | 5 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $22.67 | 1.9% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $20.73 | 1.8% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $18.17 | 1.6% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $15.70 | 1.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.00 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,170.84 | 60 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $185.25 | 10 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $166.32 | 10 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $142.74 | 7 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $107.65 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $101.83 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $97.02 | 6 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $97.02 | 6 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $76.74 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $60.69 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $60.69 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $58.36 | 3 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $58.05 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $49.72 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $49.72 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $41.57 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $22.67 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $20.73 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $18.17 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $18.17 | 1 | 2025 |
Source payment records
|
|||||
| VAQTA Normalized: vaqta |
Biological | Merck Sharp & Dohme LLC | $18.17 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $18.09 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $15.70 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.00 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $14.16 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 32 | exact normalized | Medicare Part D |
| ENTRESTO entresto |
2025 | Entresto | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 161 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 69 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 75 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 18 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 123 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
54 | 17 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
36 | 14 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
69 | 21 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
161 | 45 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
17 | 13 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
123 | 38 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
161 | 45 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
75 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
39 | 13 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
18 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
32 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Albuterol Sulfate Hfa | Albuterol Sulfate | 377 | 90 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 334 | 144 |
| Atorvastatin Calcium | Atorvastatin Calcium | 215 | 105 |
| Amlodipine Besylate | Amlodipine Besylate | 213 | 87 |
| Jardiance | Empagliflozin | 161 | 45 |
| Losartan Potassium | Losartan Potassium | 159 | 63 |
| Repatha Sureclick | Evolocumab | 135 | 37 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 126 | 54 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 123 | 38 |
| Famotidine | Famotidine | 122 | 42 |
| Alendronate Sodium | Alendronate Sodium | 120 | 57 |
| Metoprolol Succinate | Metoprolol Succinate | 115 | 46 |
| Omeprazole | Omeprazole | 105 | 44 |
| Fluticasone Propionate | Fluticasone Propionate | 99 | 39 |
| Metformin Hcl | Metformin Hcl | 98 | 53 |
| Gabapentin | Gabapentin | 95 | 42 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 88 | 27 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 87 | 40 |
| Ezetimibe | Ezetimibe | 83 | 33 |
| Lisinopril | Lisinopril | 77 | 35 |
| Mounjaro | Tirzepatide | 75 | 19 |
| Montelukast Sodium | Montelukast Sodium | 73 | 29 |
| Kerendia | Finerenone | 69 | 21 |
| Carvedilol | Carvedilol | 66 | 30 |
| Glimepiride | Glimepiride | 63 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 61 | 32 |
| Levothyroxine Sodium | Levothyroxine Sodium | 59 | 28 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 55 | 23 |
| Farxiga | Dapagliflozin Propanediol | 54 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 52 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 51 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 51 | 30 |
| Levocarnitine | Levocarnitine | 50 | 29 |
| Diclofenac Sodium | Diclofenac Sodium | 48 | 28 |
| Vascepa | Icosapent Ethyl | 48 | 16 |
| Pantoprazole Sodium | Pantoprazole Sodium | 47 | 20 |
| Meclizine Hcl | Meclizine Hcl | 46 | 17 |
| Valsartan | Valsartan | 46 | 20 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 42 | 26 |
| Lidocaine | Lidocaine | 39 | 26 |
| Trulicity | Dulaglutide | 39 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 38 | 14 |
| Symbicort | Budesonide/Formoterol Fumarate | 36 | 14 |
| Tamsulosin Hcl | Tamsulosin Hcl | 34 | 22 |
| Eliquis | Apixaban | 32 | 11 |
| Januvia | Sitagliptin Phosphate | 32 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 32 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 30 | 13 |
| Linzess | Linaclotide | 29 | 13 |
| Trazodone Hcl | Trazodone Hcl | 29 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 28 | 12 |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 27 | suppressed |
| Glipizide | Glipizide | 26 | 13 |
| Ketoconazole | Ketoconazole | 26 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 26 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 25 | 11 |
| Icosapent Ethyl | Icosapent Ethyl | 25 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 25 | 11 |
| Ammonium Lactate | Ammonium Lactate | 24 | 11 |
| Amoxicillin | Amoxicillin | 24 | 24 |
| Meloxicam | Meloxicam | 24 | 16 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 24 | 11 |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 22 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 22 | 11 |
| Ibuprofen | Ibuprofen | 21 | 15 |
| Methylprednisolone | Methylprednisolone | 21 | 18 |
| Simvastatin | Simvastatin | 21 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 21 | suppressed |
| Naproxen | Naproxen | 20 | 16 |
| Rybelsus | Semaglutide | 20 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Comfort Ez Pro Safety Pen Ndl | Pen Needle, Diabetic, Safety | 18 | suppressed |
| Furosemide | Furosemide | 18 | 14 |
| Ozempic | Semaglutide | 18 | 12 |
| Azithromycin | Azithromycin | 17 | 14 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 17 | 14 |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Cilostazol | Cilostazol | 17 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Praluent Pen | Alirocumab | 17 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 17 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 17 | 13 |
| Bydureon Bcise | Exenatide Microspheres | 16 | suppressed |
| Latanoprost | Latanoprost | 16 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 16 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 16 | suppressed |
| Entresto | Sacubitril/Valsartan | 15 | suppressed |
| Finasteride | Finasteride | 15 | suppressed |
| Spironolactone | Spironolactone | 15 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 13 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | 11 |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 11 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,170.84 · 60 records | Salix Pharmaceuticals, a division of Bausch Health US, LLC | BREZTRI, CAPVAXIVE, ELIQUIS, ENTRESTO, GARDASIL 9, IBSRELA, JARDIANCE, Kerendia, LEQVIO, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PAXLOVID, PREVNAR 20, REPATHA, REZDIFFRA, Rybelsus, TRELEGY ELLIPTA, VAQTA, Veozah, Wegovy, XIFAXAN, ZEPBOUND | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error